<DOC>
	<DOCNO>NCT02236975</DOCNO>
	<brief_summary>Prospective , multi-center , randomize 1:1 , single blind trial use BuMA Supreme versus Resolute Integrity conduct approximately 14 interventional cardiology center The Netherlands , Belgium , Spain Portugal . Clinical follow-up occur 1 , 9 12 month post-stent implantation . All patient undergo repeat angiography 9 month follow-up . QCA assessment perform baseline ( pre- post-procedure ) 9 month follow-up .</brief_summary>
	<brief_title>First-in-man Trial Examining Safety Efficacy BuMA Supreme Resolute Integrity Patients With de Novo Coronary Artery Stenosis</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>1 . The subject least 18 year age . 2 . Clinical evidence ischemic heart disease and/or positive territorial functional study . 3 . Documented stable angina pectoris ( Canadian Cardiovascular Society ( CCS ) Classification 1 , 2 , 3 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC , IIIBC ) , document silent ischemia 4 . The patient plan intervention single denovo lesion one two separate major epicardial territory ( LAD , LCX RCA ) . 5 . Diameter Stenosis≥50 and＜100 % . 6 . The visually estimate target lesion must able cover single BuMA Supreme stent single Resolute Integrity stent ( available size refer table 1 2 , page 20 21 ) . 7 . The target lesion reference diameter must visually estimate ≥2.5 mm ≤4.5 mm diameter . 8 . Written informed consent . 9 . The patient agree followup visit include 9 month angiographic followup . 10 . Patient must complete followup phase previous study . 1 . Female child bear potential ( age &lt; 50 year last menstruation within last 12 month ) . Subjects age &lt; 50 underwent tubal ligation , ovariectomy hysterectomy include . 2 . Evidence ongoing acute myocardial infarction ( AMI ) ECG and/or elevate cardiac biomarkers ( accord local standard hospital practice ) return within normal limit time procedure 3 . Patient suffer stroke/TIA last 6 month . 4 . LVEF &lt; 30 % 5 . Platelet count &lt; 100,000 cells/mm3 &gt; 400,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) 6 . Known renal insufficiency ( e.g . serum creatinine &gt; 2.5mg/dL , creatinine clearance ≤30 mL/min ) , subject dialysis , acute kidney failure ( per physician judgment ) . 7 . Patient undergo plan surgery within 6 month necessity stop DAPT . 8 . Patient require oral anticoagulation ( Coumadin , Novel Oral Anticoagulant ( NOAC ) ) 9 . History bleed diathesis coagulopathy 10 . The patient recipient heart transplant 11 . Known hypersensitivity contraindication aspirin , heparin , antiplatelet medication specify use study , sirolimus , zotarolimus , cobaltchromium . 12 . Other medical illness ( e.g . cancer , stroke neurological deficiency ) know history substance abuse ( alcohol , cocaine , heroin etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy 13 . The patient simultaneously participate another investigational device drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>